121 related articles for article (PubMed ID: 6211361)
1. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
Paridaens R; Mouridsen HT; Palshof T; Cocconi G; Van Oosterom A; Rotmensz N; Sylvester R; Heuson JC; Rozencweig M
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):67-70. PubMed ID: 6211361
[TBL] [Abstract][Full Text] [Related]
2. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
Bramwell V; Van Oosterom A; Mouridsen HT; Cheix F; Somers R; Thomas D; Rozencweig M
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):81-4. PubMed ID: 6211362
[TBL] [Abstract][Full Text] [Related]
3. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
Kleeberg UR; Mulder JH; Rümke P; Thomas D; Rozencweig M
Eur J Cancer Clin Oncol; 1982 Aug; 18(8):723-6. PubMed ID: 6217975
[TBL] [Abstract][Full Text] [Related]
4. PALA in advanced breast cancer. A phase II pilot study by the ECOG.
Taylor SG; Davis TE; Falkson G; Keller AM
Am J Clin Oncol; 1982 Dec; 5(6):627-9. PubMed ID: 7165004
[TBL] [Abstract][Full Text] [Related]
5. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Casper ES; Vale K; Williams LJ; Martin DS; Young CW
Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
[TBL] [Abstract][Full Text] [Related]
6. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
[TBL] [Abstract][Full Text] [Related]
7. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
Creagan ET; O'Connell MJ; Kovach JS
Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Weiss GR; Ervin TJ; Meshad MW; Schade D; Branfman AR; Bruni RJ; Chadwick M; Kufe DW
Cancer Chemother Pharmacol; 1982; 8(3):301-4. PubMed ID: 7127661
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Weiss GR; Ervin TJ; Meshad MW; Kufe DW
Cancer Treat Rep; 1982 Feb; 66(2):299-303. PubMed ID: 7055815
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
[TBL] [Abstract][Full Text] [Related]
11. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C
Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of combination therapy with PALA and 5-FU.
Meshad MW; Ervin TJ; Kufe D; Johnson RK; Blum RH; Frei E
Cancer Treat Rep; 1981; 65(3-4):331-4. PubMed ID: 6263472
[TBL] [Abstract][Full Text] [Related]
13. Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Presant CA; Ardalan B; Multhauf P; Chan C; Staples R; Green L; Browning S; Carr BI; Chang FF; Thayer W
Med Pediatr Oncol; 1983; 11(3):162-3. PubMed ID: 6222250
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
[TBL] [Abstract][Full Text] [Related]
15. Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.
Hart RD; Ohnuma T; Holland JF
Cancer Treat Rep; 1980; 64(4-5):617-24. PubMed ID: 6448687
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Ardalan B; Singh G; Silberman H
J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of PALA and 5-FU in patients with advanced cancer.
O'Connell MJ; Powis G; Rubin J; Moertel CG
Cancer Treat Rep; 1982 Jan; 66(1):77-80. PubMed ID: 7053270
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
Markman M; Chan TC; Cleary S; Howell SB
Cancer Chemother Pharmacol; 1987; 19(1):80-3. PubMed ID: 3815730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
